Optimizing the Suboptimal: Hepatocellular Carcinoma Surveillance Guide for Primary Care Practitioners: Based on a Medscape Education Online Activity.

Citation metadata

Author: Richard Finn
Date: May 2022
From: Journal of Family Practice(Vol. 71, Issue 4)
Publisher: Jobson Medical Information LLC
Document Type: Report
Length: 3,489 words
Lexile Measure: 2330L

Document controls

Main content

Article Preview :



The goal of this activity is to update primary care practitioners (PCPs) on risk factors and trends in hepatocellular carcinoma (HOC) development, as well as guideline recommendations and best practices for collaborating with specialists in HOC surveillance.


After participating in the activity, healthcare providers will have:

Increased knowledge regarding the

* Epidemiologic patterns associated with HCC

* Risk factors for developing HCC

* Guidelines for HCC surveillance

Greater confidence in their ability to

* Incorporate surveillance guidelines into practice

* Differentiate the roles of PCPs and specialists in HCC surveillance


This activity is intended for primary care physicians, nurse practitioners (NPs), physician assistants (PAs), and other clinicians involved In the care of patients at risk of liver cancer.


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.



Richard Finn, MD

Professor of Medicine

Geffen School of Medicine

University of California Los Angeles

Santa Monica, California

Disclosure: Richard Finn, MD, has the following relevant financial relationships:

Advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer; Bristol Myers Squibb Company; CStone Pharmaceuticals; Eisai, Inc.; Eli Lilly and Company; Genentech; Jiangsu Hengrui Medicine; Pfizer, Inc.; Roche/Genentech

Grants for clinical research from: Adaptimmune Therapeutics; Bayer; Bristol Myers Squibb Company; Eisai, Inc.; Eli Lilly and Company; Merck; Pfizer, Inc.; Roche/Genentech


Davecia Ragoonath Cameron, MS

Director of Content Development, Medscape, LLC

Disclosure: Davecia Ragoonath Cameron, MS, has no relevant financial relationships.

Tristin Abair, PhD

Senior Medical Writer, Medscape, LLC

Disclosure: Tristin Abair, PhD, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.

Peer Review

This activity has been peer reviewed and the reviewers have no relevant financial relationships.


In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

FOR PHYSICIANS: Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA


Hepatocellular carcinoma (HCC) is the most common type of liver cancer, representing the sixth most commonly diagnosed cancer and third leading cause of cancer-related death worldwide. (1,2) Specifically in the United States, over 42,000 patients were diagnosed with HCC in 2021 and this aggressive malignancy was associated with over 30,000 deaths, making it the sixth leading...

Source Citation

Source Citation   

Gale Document Number: GALE|A712558629